Navigation Links
Saladax Biomedical, Inc. Enters Agreement with Kaan Medikal for Distribution of My5-FU in Turkey
Date:8/8/2011

BETHLEHEM, Pa., Aug. 8, 2011 /PRNewswire/ -- Saladax Biomedical, Inc., a privately held company developing and commercializing novel diagnostic assays to achieve the promise of personalized medicine for new and existing therapeutics, announced today that Kaan Medikal will serve as the exclusive distributor of Saladax's My5-FU diagnostic test throughout the Turkish market.

My5-FU measures levels of 5-flourouracil (5-FU), a widely used chemotherapy drug used in conjunction with other drugs in first-line therapy for colorectal cancer and other solid tumors.  The assay technology enables oncologists to determine the optimal dose of 5-FU for each individual patient, thereby increasing the effectiveness of the drug and lessening the risk of severe toxicity and side effects.  My5-FU is the first of Saladax's innovative dose management tests commercially available.

"Kaan Medikal is an ideal partner for Saladax as we continue to expand the distribution and marketing of My5-FU in the European Union and other significant markets," said Adrienne Choma, Esq., vice president, marketing and sales of Saladax.  "Interest in Turkey for My5-FU is strong, and we expect that Kaan Medikal's market leadership in diagnostic testing and excellent reputation for quality will enable significant opportunities for growth, which will translate into improved care for patients undergoing chemotherapy treatment for colorectal and other solid tumor cancers."

Fatih Ordu, general manager of Kaan Medikal, stated, "We are delighted to be working with Saladax to market My5-FU in Turkey.  We're confident that Saladax's innovative diagnostic test will allow physicians in our country to better monitor and provide more accurate treatment to their patients."

About Saladax Biomedical, Inc.

Saladax Biomedical develops and commercializes novel diagnostic assays to achieve the promise of personalized medicine through dose management and companion di
'/>"/>

SOURCE Saladax Biomedical, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Saladax Biomedical, Inc. Completes $9 Million Debt Financing With GE Capital
2. Saladax Biomedical, Inc. Announces Pacific Rim Commercialization Team in Australia and China
3. Saladax Biomedicals 5-FU Personalized Chemotherapy Management (PCM(R)) Assay CE Marked for Distribution in the EU
4. Dainippon Sumitomo Pharma Co., Ltd. and Boston Biomedical, Inc. Enter Strategic Partnership on Anti-Cancer Drugs Targeting Cancer Stem Cells
5. BINDER BIOMEDICAL, INC. Announces Official Launch of the NEWTON™ Intervertebral Body Fusion Spinal Spacer System
6. Binder Biomedical, Inc. Announces the Release of the X-GRAFT(TM) Interspinous Device, as Part of Their QUANTUM(TM) Line of Spinal Allograft Devices, Manufactured at the University of Miami Tissue Bank
7. I-Flow Corporation Enters into Exclusive Government Distribution Agreement With Buffalo Supply, Inc.
8. Scottish Executive Awards Varian Medical Systems Major Contract to Supply Advanced Radiotherapy Equipment to Scotlands Five Cancer Centers
9. Watson Enters into Agreement to Acquire Products Related to Perrigos Acquisition of Paddock Laboratories
10. Newport Audiology Centers to Turn Up the Volume In Nashville
11. Double Eagle Holdings Enters Into Supply Agreement with Platform Delivery Technologies Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/16/2014)... 2014 This report analyzes the worldwide markets for ... Product Segments: SPECT Systems (Includes SPECT and SPECT/CT systems), and ... separate comprehensive analytics for the US, Canada ... , Asia-Pacific , Latin America ... are provided for the period 2013 through 2020. Also, a ...
(Date:9/16/2014)... 2014 This report analyzes the worldwide markets for ... Parasiticides, Vaccines, Anti-Infectives, Medicinal Feed Additives, and Others. The report ... Animals. The report provides separate comprehensive analytics for the US, ... Europe , Asia-Pacific , ... Annual estimates and forecasts are provided for the period 2013 ...
(Date:9/16/2014)... , Sept. 16, 2014  ROX Medical ... an international multi-center, prospective, randomized, controlled, blinded endpoint ... of arterial hypertension. The CONTROL-HTN trial, NCT01642498, evaluated the ... a fixed connection between a central artery and ... treatment of hypertension. The primary outcomes are reduction ...
Breaking Medicine Technology:Global Nuclear Medicine Imaging Equipment Industry 2Global Nuclear Medicine Imaging Equipment Industry 3Global Nuclear Medicine Imaging Equipment Industry 4Global Nuclear Medicine Imaging Equipment Industry 5Global Nuclear Medicine Imaging Equipment Industry 6Global Nuclear Medicine Imaging Equipment Industry 7Global Nuclear Medicine Imaging Equipment Industry 8Global Nuclear Medicine Imaging Equipment Industry 9Global Nuclear Medicine Imaging Equipment Industry 10Global Nuclear Medicine Imaging Equipment Industry 11Global Nuclear Medicine Imaging Equipment Industry 12Global Nuclear Medicine Imaging Equipment Industry 13Global Nuclear Medicine Imaging Equipment Industry 14Global Nuclear Medicine Imaging Equipment Industry 15Global Nuclear Medicine Imaging Equipment Industry 16Global Nuclear Medicine Imaging Equipment Industry 17Global Nuclear Medicine Imaging Equipment Industry 18Global Nuclear Medicine Imaging Equipment Industry 19Global Nuclear Medicine Imaging Equipment Industry 20Global Nuclear Medicine Imaging Equipment Industry 21Global Nuclear Medicine Imaging Equipment Industry 22Global Nuclear Medicine Imaging Equipment Industry 23Global Nuclear Medicine Imaging Equipment Industry 24Global Nuclear Medicine Imaging Equipment Industry 25Global Nuclear Medicine Imaging Equipment Industry 26Global Animal Medication Industry 2Global Animal Medication Industry 3Global Animal Medication Industry 4Global Animal Medication Industry 5Global Animal Medication Industry 6Global Animal Medication Industry 7Global Animal Medication Industry 8Global Animal Medication Industry 9Global Animal Medication Industry 10Global Animal Medication Industry 11
... studies including a pivotal Phase III trial in patients,with ... tablets will be presented at the Annual,Meeting of the ... June 1 - 5, 2007. , On this occasion ... on June 4, 2007. Starting at around 2:00 p.m. ...
... of Eisai's,Commitment to Oncology, WOODCLIFF LAKE, N.J., May ... abstracts covering clinical data about,their oncology pipeline compounds ... of Clinical Oncology (ASCO),annual meeting. ASCO takes place ... reveal a growing and diverse oncology clinical,development program ...
Cached Medicine Technology:Clinical Data on Eisai's Oncology Pipeline to be Presented at ASCO,Annual Meeting 2Clinical Data on Eisai's Oncology Pipeline to be Presented at ASCO,Annual Meeting 3Clinical Data on Eisai's Oncology Pipeline to be Presented at ASCO,Annual Meeting 4
(Date:9/16/2014)... UT (PRWEB) September 16, 2014 ... Solution, published new information on transitioning employees to ... Benefits, with the Affordable Care Act (ACA) in ... will be steering some or all of their ... no surprise. With guaranteed issue plans, coverage for ...
(Date:9/16/2014)... Pennsylvania (PRWEB) September 16, 2014 Holganix, ... of the fastest growing companies in the country, produces ... shrub, and tree health-care by naturally decreasing disease and ... Today it announced that it will hold its third ... Kentucky on October 22, 2014 from 1:00 P.M. through ...
(Date:9/16/2014)... UWDress.com, the well-known wedding dress manufacturer and retailer, ... assortment online. Additionally, the firm has launched a promotion ... discounts now, up to 62 percent off. ... it has won a lot of positive reviews for ... also providing big savings on many other items, including ...
(Date:9/16/2014)... Anaheim, CA (PRWEB) September 16, 2014 ... the launch of two new product extensions, an ... national headquarters, several novel marketing tools for their ... non-profit Vitamin Angels at their 5th annual national ... standing room only crowd at the Hyatt Regency ...
(Date:9/16/2014)... San Francisco) In a healthcare climate where ... potential benefit, a Yale study has found that ... procedures on elderly women with early-stage breast cancer. ... the 56th annual conference of the American Society ... Evaluating National Practice in Radiotherapy for Elderly Women: ...
Breaking Medicine News(10 mins):Health News:Zane Benefits Publishes New Information on Transitioning Employees to Individual Health Insurance 2Health News:Holganix Holds 3rd Annual Bionutrional Summit in Louisville, Kentucky 2Health News:New Elegant Evening Wear Assortment Released By UWDress.com 2Health News:New Products Announced at Jusuru International’s R2E14 National Convention 2Health News:New Products Announced at Jusuru International’s R2E14 National Convention 3Health News:New Products Announced at Jusuru International’s R2E14 National Convention 4
... A new study shows that estrogen therapy does not ... postmenopausal women, say researchers //.Previous studies have reported an ... dementia. ,A placebo-controlled trial of estrogen or estrogen ... looked at associated risk for dementia. In the estrogen-only ...
... in your 20s could reduce the risk of developing high ... psychological stress with spikes in blood pressure are more likely ... 40s. ,Specialists say assessing blood pressure changes in response ... person’s future risk of high blood pressure. In a large ...
... shows dogs may be able to anticipate seizures in ... dogs in this study was // licking, often ... and “protective" behavior without aggression. In previous studies, owners ... even prevent their seizures. Some breeds of seizure-alerting ...
... patients consume about 40 milligrams of vitamin C daily ... vitamin C may protect against rheumatoid arthritis. ,Researchers ... 45 and 74. Participants' diets were assessed by using ... in two or more joints for at least one ...
... with a number of other side effects. For some people ... through with it may not even get rid of their ... to delivering chemotherapy. ,Perfusion therapy is the most aggressive ... avoid the toxicity to the rest of the body .Blood ...
... might help protect the eyes against a leading cause of ... // men and women it was found that those ... had a 36-percent lower risk of developing age-related maculopathy than ... have linked consumption of antioxidant vitamins and minerals to lower ...
Cached Medicine News:
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: